A Multiomics Study of Tumor Evolution Characteristics and Prognostic Model in Early-stage Non-small Cell Lung Cancer
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Non-small Cell Lung Cancer
- Sponsor
- Peking University People's Hospital
- Enrollment
- 300
- Locations
- 1
- Primary Endpoint
- Disease-free survival (DFS)
- Status
- Recruiting
- Last Updated
- last year
Overview
Brief Summary
The purpose of this study is to determine the evolutionary mechanism of early-stage non-small cell lung cancer and establish an accurate prognostic model and a recurrence monitoring system by multiomics analysis, which can be helpful for the individual and whole management of lung cancer patients and improve the overall prognosis.
Detailed Description
Lung cancer is the leading cause of cancer-related death globally. Non-small cell lung cancer (NSCLC) accounts for 85% of lung cancer and surgery is still the main treatment strategy. This study will determine the evolutionary mechanism of early-stage non-small cell lung cancer and establish an accurate prognostic model and a recurrence monitoring system by multiomics analysis, which can be helpful for the individual and whole management of lung cancer patients and improve the overall prognosis.
Investigators
Jun Wang
Member of the Chinese Academy of Engineering
Peking University People's Hospital
Eligibility Criteria
Inclusion Criteria
- •Age ≥ 18 years old;
- •Early-stage NSCLC patients underwent radical surgical resection;
- •Sufficient tumor tissue and blood sample for study use;
- •Available clinical-pathologic data, imaging data and follow-up date;
- •Written informed consent.
Exclusion Criteria
- •History of other malignant tumors;
- •Evidence of distant metastasis before surgery;
- •Insufficient tumor tissue or blood sample for study use;
- •Clinical-pathologic data, imaging data or follow-up date is not available;
- •Other judgments by the Investigator that the patient should not participate in the study.
Outcomes
Primary Outcomes
Disease-free survival (DFS)
Time Frame: Through study completion, an average of 2 years
Time from randomization to disease recurrence or death from any cause.
Overall survival (OS)
Time Frame: Through study completion, an average of 2 years
Time from randomization to death from any cause.
Secondary Outcomes
- Relationship between translational biomarkers and clinical outcome(Through study completion, an average of 2 years)